Stanazol

Quick links to important sections

Stanazol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stanazol

What is Stanazol? An Overview of Identity and Purpose

Property Description
Active ingredient Stanozolol
Form Oral tablet, Aqueous suspension (injectable)
Pharmacological class Anabolic-Androgenic Steroid (AAS)
General purpose Supports tissue building and regeneration
Origin Synthetic (derived from dihydrotestosterone)

What is Stanazol? The Definitive Classification

Stanazol is the trade name for a medication whose active compound is Stanozolol, which is chemically categorized as a synthetic androgen belonging to the pharmacological class of Anabolic-Androgenic Steroids (AAS). The compound's structural modifications, including a unique pyrazole ring and C17alpha-alkylation, define its distinct therapeutic properties and oral bioavailability. Stanozolol was initially introduced in 1962, establishing its recognized role in medicine.

Composition and Available Forms of Stanozolol

The product is a single-entity preparation, meaning it contains only the active substance Stanozolol, confirming its origin as a purely synthetic organic compound. Stanozolol is distinguished from many other anabolic agents by its availability in two primary high-level forms: as an oral tablet and as an aqueous suspension administered by intramuscular injection. Clinical research has affirmed the stability of the oral formulation, which relies on the C17alpha-alkylation structure to resist immediate liver breakdown.

The General Purpose of This Anabolic Compound

The primary function of this anabolic compound is directly related to its classification: it is clinically recognized for supporting tissue synthesis. This action is achieved by encouraging cellular protein synthesis and fostering a positive nitrogen balance. This mechanism is intended to support the body in building and maintaining lean body mass and bone density, a function typically employed in scenarios requiring the reversal of tissue wasting.

What side effects are possible with Stanazol?

Possible Side Effects and Safety Information

The officially documented safety profile for Stanazol (Stanozolol) is categorized by System-Organ Classes and frequency, focusing on specific risks outlined in regulatory documents. Adverse reactions are primarily grouped by the organ systems they affect, with significant emphasis placed on the potential for severe, dose-dependent effects.

Adverse Reaction Classifications

Classification Tier Documented Effects (Examples)
Common New or worsening acne, difficulty sleeping, headache, and changes in sexual desire.
Rare Serious and potentially fatal liver problems.

The most critical adverse reactions pertain to the Hepatic/Hepatobiliary Disorders, including documented cases of Peliosis Hepatis (blood-filled cysts in the liver), Hepatic Neoplasms, and Hepatocellular Carcinomas. These life-threatening conditions have been associated with prolonged therapy with high doses and are explicitly listed as serious adverse reactions.

Population-Specific and Gender-Related Safety

Official regulatory documents detail specific safety considerations for certain patient groups:

  • Female Patients: There is a defined risk of Virilization (e.g., voice deepening, clitoral enlargement, hirsutism). Regulatory information notes that clitoral enlargement is not reversible and that prompt discontinuation upon signs of mild virilization may prevent irreversible changes.
  • Prepubertal Patients: Use in this group carries the risk of termination of linear bone growth by premature closure of the epiphyseal growth centers.

Usage is subject to strict Contraindications, including known or suspected carcinoma of the prostate or male breast cancer, severe liver disease, hypercalcemia, and use during pregnancy or lactation. The compound may also affect clotting factors and blood glucose tolerance.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Stanazol (Stanozolol) overdose addresses both the acute event and the risks associated with chronic, high-dose use.

Overdose scope Official Regulatory Statement
Documented overdose presentations Acute overdosage is associated with gastrointestinal upset and nausea. Some regulatory information notes that specific symptoms of overdose are not known.
Physiological systems affected Acute effects primarily involve the Gastrointestinal system. Warnings concerning chronic, excessive use involve the Hepatic and Cardiovascular systems, including risk of heart attack and stroke.
Dose-related or exposure-related factors An acute overdose event is officially described as unlikely to threaten life. Severe risks are documented warnings linked to chronic, non-prescribed, or excessive use.
Emergency-response statements Contact an emergency room or a poison control center immediately for advice if an overdose is suspected.
When immediate medical help is required Seek emergency medical services (such as 911) if the person exhibits acute life-threatening signs, including collapse, seizure, or trouble breathing.

Overdose classifications (high-level)

Category Official Regulatory Classification/Statement
Severity classification Acute event is categorized as unlikely to threaten life.
Overdose-context constraints Management is restricted to supportive care only, as no specific antidote is available.

Official overdose statements:

  • Acute overdosage is described as being unlikely to threaten life.
  • Documented management is based solely on supportive care, with no specific antidote available.
  • The required action is to contact a poison control center or emergency room immediately upon suspicion of overdose.
  • Chronic, excessive use of this drug class is officially linked to severe outcomes, including stroke and heart attack.

Regulatory documents define the official overdose profile by distinguishing the low risk associated with acute, single-event intoxication from the serious, life-threatening complications that government warnings associate with chronic misuse. The mandated action for a suspected overdose is to immediately contact emergency medical services or a poison control center, confirming the requirement for professional assessment and supportive intervention.

Therapeutic Uses of Stanazol

What Stanazol Treats: Main Uses and Benefits

Stanazol is commonly used for managing conditions involving recurrent symptomatic distress and symptoms related to systemic imbalance and noticeable physiological strain. The medication is relevant for managing symptoms across distinct domains, including the supportive relief during phases of recurrent manifestations in Hereditary Angioedema (HAE), care for chronic tissue wasting, and addressing specific vascular disorders that lead to persistent symptoms related to inflammatory or irritative states.

The therapeutic domains of use are relevant for easing symptom clusters that may become intense or disruptive during episodes of heightened physiological activity. The benefit provides support that helps ease the overall symptom burden associated with severe manifestations and contributes to easing the overall symptom load during periods of heightened symptoms.

“This medication is applied in addressing structural health and may help patients cope more steadily with symptom fluctuations during symptomatic phases.”

In cases involving bone density loss (e.g., in osteoporosis), the medicine is used for managing symptoms linked to organ-specific functional stress and is relevant for easing discomfort linked to tissue wasting. In vascular conditions, it is considered relevant for easing symptoms that interfere with daily comfort by supporting the local tissue environment.


Quick Fact: Relief for Chronic Tissue Wasting Stanazol is commonly used to help with the maintenance of lean body mass and net bone mass, supporting patients during catabolic states and is applied in addressing the noticeable physiological strain linked to chronic conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Stanazol? Official Regulatory Information

The official eligibility profile for Stanazol (Stanozolol) is defined by strict regulatory exclusions and mandatory caution required for specific populations, as documented in government prescribing information.

Absolute Non-Eligibility (Contraindications)

Stanazol is formally contraindicated and must not be used by several patient groups, including:

  • Male patients with known or suspected carcinoma of the breast or prostate.
  • Patients diagnosed with severe hepatic, renal, or cardiac dysfunction.
  • Women who are pregnant (due to fetal virilization risk) or lactating (breastfeeding).
  • Any patient with hypercalcemia (a high level of calcium in the blood).

Population Restrictions and Cautionary Use

Use is restricted in children due to the risk of accelerating bone maturation, which can compromise adult stature. Geriatric male patients require caution and monitoring due to an increased risk for prostatic hypertrophy.

Caution is required for patients with comorbidities such as Diabetes Mellitus, bleeding disorders, and those with non-severe preexisting cardiac, liver, or kidney problems, due to the risk of fluid retention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Stanazol (Stanozolol) has documented interaction patterns with several categories of medicinal products, as detailed in official regulatory labeling. These interactions are primarily classified as pharmacodynamic or additive effects.

Oral Anticoagulants: The concurrent use of Stanazol with Vitamin K antagonist anticoagulants (e.g., Warfarin) is officially noted to increase the anticoagulant's activity. This increase is a consequence of the suppression of specific hepatic clotting factors, including factors II, V, VII, and X. The official regulatory profile requires specific procedural constraints, namely the frequent monitoring of the International Normalized Ratio (INR) and Prothrombin Time (PT) to manage this effect.

Antidiabetic Agents and Hypoglycemics: An additive effect is documented when Stanazol is used concurrently with hypoglycemic agents, including Insulin and oral antidiabetic medicines. This pharmacodynamic interaction increases the risk of lowered blood glucose, which may necessitate an adjustment to the dose of the antidiabetic regimen by the prescribing authority.

Adrenal Cortical Steroids: Use with adrenal cortical steroids or ACTH (Corticosteroids) carries an officially noted additive risk of fluid retention and edema. A population-specific constraint exists for this combination, as the risk of severe edema is heightened in patients with pre-existing cardiac, renal, or hepatic disease.

Laboratory Test Interference: A documented non-drug-drug interaction involves specific laboratory measurements. Stanozolol may cause a decrease in the serum concentration of Thyroxine-binding Globulin (TBG), which can impact the interpretation of certain thyroid function assays by altering the total T4 measurement.

Mechanism of Action

Stanazol, a synthetic 17alpha-alkylated derivative of dihydrotestosterone, functions as an agonist of the Androgen Receptor (AR), a nuclear transcription factor primarily located in the cytosol of target cells such as skeletal muscle.

Upon cellular entry, Stanazol binds to the cytosolic AR, forming a ligand-receptor complex. This complex then undergoes translocation to the cell nucleus, where it binds to specific Androgen Response Elements (AREs) in the promoter regions of target genes. This DNA binding event modulates gene transcription, resulting in the altered synthesis of various cellular proteins. The downstream cascade includes enhanced nitrogen retention and an increased rate of protein synthesis, particularly in muscle and bone tissue.

Stanazol also exhibits binding activity at other targets. It reduces the concentration of Sex Hormone-Binding Globulin (SHBG) in the circulation, which consequently increases the concentration of unconjugated, biologically active androgens. Furthermore, Stanazol stimulates the production of C1-inhibitor in the liver and enhances fibrinolytic activity by increasing the synthesis of tissue plasminogen activator and decreasing plasminogen activator inhibitor-1, leading to systemic modulation of the complement and coagulation cascades.

Dosage and Administration Information

How Stanazol Is Used: Official Administration Guidelines

This section outlines the precise methods and patterns for administering Stanazol (Stanozolol) as specified in official prescribing documents for its approved uses.

Approved Administration and Dosage

Stanazol is officially administered via the oral route when using the tablet form. The standard official dosage regimen for adults is structured in two phases: an initial phase and a maintenance phase.

Dosing Phase Dosing Frequency and Strength (HAE Prophylaxis)
Initial Dose 2 mg orally, three times a day (TID), totaling 6 mg/day.
Maintenance Dose Reduced to the minimum effective dose, often 2 mg once per day.

Procedural and Usage Structure

The usage protocol is defined by a mandatory titration sequence. After achieving a favorable clinical response, the dosage must be gradually reduced over time to establish the lowest effective maintenance level. This dose reduction is typically performed in small decrements at intervals of one to three months. This process ensures the medication is used strictly according to the minimum necessary level.

Key Administration Instructions

When taking the oral tablet, administration is governed by the following practical rules:

  • Ingestion: The tablet should be taken with a full glass of water.
  • Food: Stanazol can be administered with or without food.
  • Schedule: The medication must be taken regularly (at consistent intervals) to maximize its benefit, avoiding arbitrary dosing schedules.

These official instructions establish a controlled, time-bound protocol, defining the consistent use and subsequent gradual reduction of the oral dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Stanazol

1. Evidence for use in Hereditary Angioedema (HAE)

The compound was studied for its use in Hereditary Angioedema (HAE), a condition characterized by fluctuating or episodic manifestations. The evidence base includes historical clinical trials and long-term observational follow-up studies, some applied in research contexts involving fluctuating or unstable symptoms. These studies monitored outcomes related to episodic or acute changes in the frequency and severity of symptomatic attacks.

Findings describe patterns observed in attack frequency in observed patient cohorts. Studies monitored symptomatic patterns and stability over extended periods. Research examined specific complement component levels in relation to the compound's use. What remains uncertain is the need for more recent, large-scale randomized controlled trials (RCTs). Comparative evidence is lacking.


2. Evidence for Chronic Tissue Wasting and Bone Density Loss

Stanazol was evaluated in historical double-blind clinical trials exploring its adjunctive use in conditions associated with systemic or functional imbalance, such as chronic tissue-depleting processes and certain forms of bone density loss (e.g., in postmenopausal women). Research examined outcomes related to changes in total bone mass, lean body mass (LBM), and measures of nitrogen balance.

Regulatory reviews described data patterns related to use as an adjunct rather than a primary treatment. Studies reported how total bone mass evolved in the observed postmenopausal populations over defined time intervals. Evidence quality varies across studies due to the historical nature of the bulk of this research. Follow-up durations were limited in many trials.


3. Evidence for use in Specific Vascular Disorders

Stanazol was observed in a specialized and smaller body of research exploring short-term symptom patterns in specific vascular conditions, such as lipodermatosclerosis. The limited evidence base included randomized trials that monitored patient-reported outcomes describing perceived discomfort and objective measurements of skin characteristics.

Other findings indicate measurements related to ulcer healing, though findings were mixed or inconsistent across various studies. The research base for this application is limited, meaning results apply only to the populations studied and the limited evidence quality means certainty remains low for this specialized application.

Frequently Asked Questions (FAQ)

Common questions about Stanazol (FAQ)


Q: What is Stanazol primarily used for?

The primary therapeutic use of this compound, as described in official U.S. and international regulatory labeling, is for the prophylactic (preventive) treatment of Hereditary Angioedema (HAE). HAE is a rare genetic condition characterized by episodes of severe swelling.


Q: Is Stanazol the same type of medicine as other drugs I've heard about?

Stanazol is chemically defined as a synthetic androgen. According to regulatory classification, it belongs to the pharmacological class of Anabolic-Androgenic Steroids (AAS). This classification defines its general structure and therapeutic properties.


Q: Does Stanazol cause long-term side effects?

Official documents indicate that severe, potentially fatal liver effects have been associated with prolonged use at high doses. These risks include blood-filled cysts in the liver (Peliosis Hepatis) and hepatic cancers. For this reason, regulatory dosage regimens are structured to require a reduction to the lowest effective maintenance level.


Q: Is there a maximum time someone is generally advised to use Stanazol?

Regulatory instructions guide a dosage reduction over an interval of one to three months to establish the lowest effective maintenance dose. This regulatory approach is based on the observation that severe liver problems are associated with prolonged therapy.


Q: What should I do if I forget to take my Stanazol dose?

Official patient guidance states that a forgotten dose is generally taken when remembered. However, if it is nearly time for the next scheduled dose, the forgotten dose should be skipped entirely. Regulatory sources strongly specify patients not to take a double dose to make up for a missed one.


Q: What kind of medical monitoring is usually required while taking Stanazol?

Official documentation indicates that medical monitoring is generally required to track the drug's effects and watch for potential side effects. This monitoring may include frequent blood tests or other evaluations. Specific monitoring requirements, such as checking blood clotting time, are in place for patients using certain other medications concurrently.


Q: What is the risk of dependence or addiction with Stanazol?

Stanazol is federally classified as a Schedule III controlled substance by the U.S. Drug Enforcement Administration. This classification exists because the drug has a recognized potential for abuse and physical or psychological dependence.


Q: Is the Stanazol dosage based on body weight?

The recommended dosing for adults, as outlined in official prescribing information, is a fixed quantity (e.g., 2 mg orally, three times a day) during the initial phase. The dosage regimen described in official prescribing information is structured around titration to the lowest effective dose, rather than weight-based calculation.


Q: Does Stanazol have a risk of allergic reaction?

Yes. Official warnings describe the potential for a severe allergic reaction to the medication. Signs of such a reaction, including difficulty breathing or swelling of the face, throat, or tongue, are considered serious and require immediate medical attention.


Q: Does Stanazol have any known effect on fertility?

Official regulatory information indicates that the use of this medication may cause temporary infertility in some male patients by affecting sperm production. In female patients, the use of Stanazol can also lead to menstrual irregularities.


Q: Does Stanazol interact with alcohol consumption?

Regulatory patient information often states that there are generally no restrictions on food, beverages, or activities unless otherwise directed by a healthcare provider. The potential interaction with alcohol is typically a point of discussion with a healthcare provider.


Q: Are there any specific lifestyle changes recommended when using Stanazol?

Regulatory patient information often states that there are generally no restrictions on food, beverages, or activities unless otherwise directed by a healthcare provider. Patients are expected to follow the prescribed administration schedule consistently.


Q: Are there any common supplements or vitamins that interact with Stanazol?

Official regulatory documents advise patients to consult with a healthcare provider before using any vitamins, minerals, or herbal products while taking this medication. Regulatory documents suggest that consultation is generally recommended because specific interaction data for many supplements may not be listed in the main drug label.


Q: What if I'm using herbal remedies; can I still take Stanazol?

Regulatory documents advise consulting a healthcare provider before using any herbal products while taking this medication. This consultation is generally recommended to assess whether the herbal product could interfere with the prescribed medication or contribute to the risk of side effects.


Q: What happens if I accidentally take two doses of Stanazol close together?

Official guidance states that an acute overdose of the medication is generally unlikely to threaten life. In cases where an overdose is suspected, official sources specify that a poison control center or emergency room can be contacted for guidance.


Q: Does Stanazol interact with birth control pills?

Stanazol is noted to potentially cause changes in menstrual cycles and other hormonal effects in female patients. Due to the potential for the medication to affect sex hormone levels, patients using hormonal contraceptives are directed to consult their healthcare provider for guidance.


Q: Does Stanazol cause changes in mood or anxiety?

The official adverse reaction list for Stanazol does not list mood or anxiety changes as a common effect. However, other medications in the same class (Anabolic-Androgenic Steroids) are generally associated with a potential for psychological effects or mood changes.


Q: Is it common to feel tired or dizzy when first starting Stanazol?

The most common side effects listed in the official product information include new or worsening acne, difficulty sleeping, headache, and changes in sexual desire. Official regulatory lists of common adverse reactions do not typically include fatigue or dizziness. If symptoms such as fatigue or dizziness are observed, consultation with a medical professional is described as a typical next step.

How should Stanazol be stored and disposed of?

Official Storage and Disposal Requirements

Stanozolol must be stored according to strict regulatory guidelines to maintain potency and ensure security as a controlled substance.

Storage Component Official Requirement
Temperature Store at room temperature, typically 15 C to 30 C (59 F to 86 F).
Environment Protect from light, excess heat, and moisture. Keep container tightly closed.
Security As a controlled substance, store securely in a locked location out of the sight and reach of children.
Disposal Dispose of unused or expired product in accordance with local regulations, often utilizing drug take-back programs. Avoid disposal into wastewater.

These official conditions define the required environment—a cool, dark, and dry setting—and mandate security due to its classification. Disposal must adhere to specific legal requirements to ensure proper handling and environmental safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stanazol found in:

A-Z Index: